SEMABIZ, Inc. | ChosaReport.com

日本と海外の市場調査レポート＆サービスを取り扱っております。

CNTX-4975 – 変形性関節症治療薬のパイプライン

CNTX-4975 OSTEOARTHRITIS DRUG PIPELINE

CNTX-4975 - 変形性関節症治療薬のパイプライン – 市場インサイトと2032年までの予測
CNTX-4975 OSTEOARTHRITIS DRUG PIPELINE – MARKET INSIGHTS AND FORECASTS UPTO 2032
出版社Inkwood Research
出版年月2024年9月
ページ数43
価格タイプシングルユーザライセンス
価格USD 550
種別英文調査報告書

Report Overview

KEY INSIGHTS

CNTX-4975 is currently being evaluated as a treatment for moderate to severe knee osteoarthritis (OA) pain. It is a highly purified, synthetic form of trans-capsaicin administered via injection directly to the pain site. This innovative treatment harnesses capsaicin’s natural analgesic properties, aiming to provide rapid, long-lasting, and targeted pain relief.

CNTX-4975 further works by targeting the TRPV1 receptor, which deactivates local pain fibers that transmit pain signals to the brain. This mechanism can potentially offer pain relief lasting up to six months until the affected pain fibers regenerate. Its precise delivery and selective action allow for effective pain management without affecting other nerve functions.

Developed by Centrexion Therapeutics, CNTX-4975 is part of the company’s commitment to addressing unmet needs in chronic pain management through non-opioid, non-addictive treatments. Centrexion Therapeutics, founded in 2013 and headquartered in Boston, focuses on developing a broad pipeline of pain management therapies, including topical gels, joint and deep tissue injections, spinal delivery methods, and three distinct oral therapies.

MARKET POTENTIAL AND POSITIONING

CNTX-4975, the flagship product candidate from Centrexion Therapeutics, is strategically poised in the market as a promising non-opioid therapy for osteoarthritis, specifically for the treatment of moderate to severe knee osteoarthritis (OA) pain. Currently, in Phase III clinical trials, CNTX-4975 introduces a novel approach by using an ultra-pure, synthetic form of trans-capsaicin and TRPV1 receptor agonists delivered directly to the pain site via injection. This targeted delivery method is designed to offer effective, long-lasting pain relief while avoiding the risks commonly associated with opioid treatments.

Moreover, the completion of patient enrollment in the third Phase III trial, VICTORY-3, in September 2019 highlights the company’s dedication to optimizing the administration process and improving patient comfort. The VICTORY-3 trial, which includes a single injection per knee in 857 participants, is designed to assess both the efficacy and safety of a 1.0 mg dose of CNTX-4975 in patients experiencing chronic, moderate to severe knee OA pain.

REGIONAL ANALYSIS

Inkwood Research offers an analysis of seven key markets:
• United States
• Germany
o In Germany, the growing elderly population and rising obesity rates are key factors driving the increasing prevalence of osteoarthritis, particularly in weight-bearing joints such as the knees and hips. This condition places a significant strain on the healthcare system, creating a strong demand for medical treatments, knee osteoarthritis rehabilitation services, and joint replacement surgeries.
o According to industry sources, in 2023, there were 18.89 million individuals in Germany aged 65 years or older. Knee and hip joints are most frequently impacted, resulting in considerable pain, stiffness, and decreased mobility.
• France
• United Kingdom
• Italy
• Spain
• Japan

Table of Contents

TABLE OF CONTENTS
1. INTRODUCTION TO THE REPORT
2. CNTX-4975 OVERVIEW
2.1. PRODUCT DETAIL
2.2. CLINICAL DEVELOPMENT
2.2.1. CLINICAL STUDIES
2.2.2. CLINICAL TRIALS INFORMATION
2.2.3. SAFETY AND EFFICACY
2.3. OTHER DEVELOPMENTAL ACTIVITIES
2.4. PRODUCT PROFILE
3. COMPETITIVE LANDSCAPE
3.1. MARKETED THERAPIES
3.2. LATE-STAGE EMERGING THERAPIES
4. CNTX-4975 MARKET ASSESSMENT
4.1. MARKET OUTLOOK OF CNTX-4975 IN OSTEOARTHRITIS
5. 7 MAJOR MARKET’S ANALYSIS
5.1. MARKET SIZE OF CNTX-4975 IN THE 7 MAJOR MARKETS FOR OSTEOARTHRITIS
5.2. 7 COUNTRY ANALYSIS
5.2.1. MARKET SIZE OF CNTX-4975 IN UNITED STATES FOR OSTEOARTHRITIS
5.2.2. MARKET SIZE OF CNTX-4975 IN GERMANY FOR OSTEOARTHRITIS
5.2.3. MARKET SIZE OF CNTX-4975 IN FRANCE FOR OSTEOARTHRITIS
5.2.4. MARKET SIZE OF CNTX-4975 IN ITALY FOR OSTEOARTHRITIS
5.2.5. MARKET SIZE OF CNTX-4975 IN SPAIN FOR OSTEOARTHRITIS
5.2.6. MARKET SIZE OF CNTX-4975 IN UNITED KINGDOM FOR OSTEOARTHRITIS
5.2.7. MARKET SIZE OF CNTX-4975 IN JAPAN FOR OSTEOARTHRITIS
6. SWOT ANALYSIS
7. ANALYST PERSPECTIVE

List of Tables

LIST OF TABLES
TABLE 1: CNTX-4975, CLINICAL TRIAL DESCRIPTION, 2024
TABLE 2: CNTX-4975, GENERAL DESCRIPTION
TABLE 3: MARKETED THERAPIES
TABLE 4: EMERGING THERAPIES
TABLE 5: CNTX-4975 MARKET SIZE IN THE 7 MAJOR MARKETS, IN $ MILLION (2019–2032)
TABLE 6: CNTX-4975 MARKET SIZE IN UNITED STATES, IN $ MILLION (2019–2032)
TABLE 7: CNTX-4975 MARKET SIZE IN GERMANY, IN $ MILLION (2019–2032)
TABLE 8: CNTX-4975 MARKET SIZE IN FRANCE, IN $ MILLION (2019–2032)
TABLE 9: CNTX-4975 MARKET SIZE IN ITALY, IN $ MILLION (2019–2032)
TABLE 10: CNTX-4975 MARKET SIZE IN SPAIN, IN $ MILLION (2019–2032)
TABLE 11: CNTX-4975 MARKET SIZE IN UNITED KINGDOM, IN $ MILLION (2019–2032)
TABLE 12: CNTX-4975 MARKET SIZE IN JAPAN, IN $ MILLION (2019–2032)

List of Figures

LIST OF FIGURES
FIGURE 1: CNTX-4975 MARKET SIZE IN THE 7 MAJOR MARKETS, IN $ MILLION (2019–2032)
FIGURE 2: CNTX-4975 MARKET SIZE IN UNITED STATES, IN $ MILLION (2019–2032)
FIGURE 3: CNTX-4975 MARKET SIZE IN GERMANY, IN $ MILLION (2019–2032)
FIGURE 4: CNTX-4975 MARKET SIZE IN FRANCE, IN $ MILLION (2019–2032)
FIGURE 5: CNTX-4975 MARKET SIZE IN ITALY, IN $ MILLION (2019–2032)
FIGURE 6: CNTX-4975 MARKET SIZE IN SPAIN, IN $ MILLION (2019–2032)
FIGURE 7: CNTX-4975 MARKET SIZE IN UNITED KINGDOM, IN $ MILLION (2019–2032)
FIGURE 8: CNTX-4975 MARKET SIZE IN JAPAN, IN $ MILLION (2019–2032)

医療・医薬の最新記事8件